Egf Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| EGF Gene | |
|---|---|
| Full Name | Epidermal Growth Factor |
| Chromosome | 4q25 |
| NCBI Gene ID | 1950 |
| OMIM | 131530 |
| Ensembl ID | ENSG00000138798 |
| UniProt ID | P01133 |
| Associated Diseases | Alzheimer's Disease; Parkinson's Disease; Stroke; Peripheral Neuropathy |
The EGF (Epidermal Growth Factor) gene encodes a 53-amino acid mitogenic peptide that binds to the EGF receptor (EGFR/HER1). EGF binding activates multiple downstream signaling pathways including MAPK/ERK, PI3K/AKT, and PLCγ, promoting cell proliferation, differentiation, and survival. In the nervous system, EGF acts as a neurotrophic factor supporting neuronal survival, stimulating neurogenesis, and enhancing synaptic plasticity. EGF has demonstrated neuroprotective effects in experimental models of Parkinson's disease, Alzheimer's disease, and stroke.
Epidermal growth factor (EGF) is a mitogenic peptide that stimulates cell proliferation and differentiation. It binds to the EGFR and activates signaling pathways important for neuronal survival and synaptic plasticity.
EGF is a 53-amino acid growth factor that binds to the EGF receptor (EGFR/HER1) with high affinity. EGF binding activates EGFR tyrosine kinase activity, triggering downstream signaling through MAPK/ERK, PI3K/AKT, and PLCγ pathways. EGF promotes neuronal survival, stimulates neurogenesis, and enhances synaptic plasticity. In the brain, EGF is involved in neural progenitor cell proliferation and differentiation. EGF has neuroprotective effects in models of PD, stroke, and AD.
Alzheimer's Disease; Parkinson's Disease; Stroke; Peripheral Neuropathy
EGF is expressed in many tissues including brain, kidney, salivary gland, and duodenum. In the brain, EGF is expressed in neurons and astrocytes and acts as a trophic factor for various neuronal populations.
EGF has significant clinical relevance in neurodegenerative diseases. In Alzheimer's disease, EGF and EGFR signaling are altered in the brain, with decreased EGF receptor expression in the hippocampus. EGF has been investigated as a potential therapeutic agent for neurodegenerative conditions due to its neurotrophic effects. Clinical trials have explored EGF delivery for Parkinson's disease and other neurodegenerative disorders.
Current research focuses on understanding EGF's role in neuroprotection, developing EGF-based therapies that can cross the blood-brain barrier, investigating EGF combination therapies with other neurotrophic factors, and exploring gene therapy approaches for EGF delivery to the brain.
The study of Egf Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.